- Home
- GDV vs MIRM Comparison
GDV vs MIRM Comparison
Compare GDV & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDV
- MIRM
- Stock Information
- Founded
- GDV 2003
- MIRM 2018
- Country
- GDV United States
- MIRM United States
- Employees
- GDV N/A
- MIRM N/A
- Industry
- GDV Investment Managers
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- GDV Finance
- MIRM Health Care
- Exchange
- GDV Nasdaq
- MIRM Nasdaq
- Market Cap
- GDV 2.2B
- MIRM 1.9B
- IPO Year
- GDV N/A
- MIRM 2019
- Fundamental
- Price
- GDV $24.50
- MIRM $44.50
- Analyst Decision
- GDV
- MIRM Strong Buy
- Analyst Count
- GDV 0
- MIRM 13
- Target Price
- GDV N/A
- MIRM $57.00
- AVG Volume (30 Days)
- GDV 186.0K
- MIRM 340.6K
- Earning Date
- GDV 01-01-0001
- MIRM 11-12-2024
- Dividend Yield
- GDV 5.81%
- MIRM N/A
- EPS Growth
- GDV N/A
- MIRM N/A
- EPS
- GDV N/A
- MIRM N/A
- Revenue
- GDV N/A
- MIRM $307,028,000.00
- Revenue This Year
- GDV N/A
- MIRM $73.07
- Revenue Next Year
- GDV N/A
- MIRM $27.98
- P/E Ratio
- GDV N/A
- MIRM N/A
- Revenue Growth
- GDV N/A
- MIRM 112.14
- 52 Week Low
- GDV $18.04
- MIRM $23.14
- 52 Week High
- GDV $23.00
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- GDV 49.22
- MIRM 65.32
- Support Level
- GDV $23.96
- MIRM $41.09
- Resistance Level
- GDV $25.33
- MIRM $48.89
- Average True Range (ATR)
- GDV 0.24
- MIRM 2.16
- MACD
- GDV 0.01
- MIRM 0.57
- Stochastic Oscillator
- GDV 39.05
- MIRM 59.09
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food & Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.